IBRX (STOCKS)
ImmunityBio, Inc. Common Stock
$7.283100
+0.003100 (+0.04%)
Prev close: $7.280000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Richard Adcock
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7,489.79M
- Employees
- 685
- P/E (TTM)
- -18.73
- P/B (TTM)
- -14.76
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $113.29M |
| Benefits Costs and Expenses | $464.90M |
| Cost Of Revenue | $753.00K |
| Costs And Expenses | $369.32M |
| Gross Profit | $112.54M |
| Nonoperating Income/Loss | -$95.58M |
| Operating Expenses | $368.56M |
| Operating Income/Loss | -$256.03M |
| Income/Loss From Continuing Operations After Tax | -$351.47M |
| Income/Loss From Continuing Operations Before Tax | -$351.61M |
| Income/Loss From Equity Method Investments | $0.00 |
| Income Tax Expense/Benefit | -$135.00K |
| Income Tax Expense/Benefit, Current | $4.00K |
| Income Tax Expense/Benefit, Deferred | -$139.00K |
| Interest Expense, Operating | $60.89M |
| Net Income/Loss | -$351.47M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$74.00K |
| Net Income/Loss Attributable To Parent | -$351.40M |
| Net Income/Loss Available To Common Stockholders, Basic | -$351.40M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.38 |
| Diluted Earnings Per Share | -$0.38 |
| Basic Average Shares | 919,863,000 |
| Diluted Average Shares | 919,863,000 |
| Assets | $501.90M |
| Current Assets | $314.88M |
| Inventory | $910.00K |
| Other Current Assets | $313.97M |
| Noncurrent Assets | $187.02M |
| Fixed Assets | $114.26M |
| Other Non-current Assets | $72.76M |
| Liabilities | $1.00B |
| Current Liabilities | $61.75M |
| Noncurrent Liabilities | $939.72M |
| Equity | -$499.57M |
| Equity Attributable To Noncontrolling Interest | $895.00K |
| Equity Attributable To Parent | -$500.47M |
| Liabilities And Equity | $501.90M |
| Net Cash Flow From Operating Activities | -$304.94M |
| Net Cash Flow From Operating Activities, Continuing | -$304.94M |
| Net Cash Flow From Investing Activities | -$149.80M |
| Net Cash Flow From Investing Activities, Continuing | -$149.80M |
| Net Cash Flow From Financing Activities | $400.24M |
| Net Cash Flow From Financing Activities, Continuing | $400.24M |
| Net Cash Flow | -$54.50M |
| Net Cash Flow, Continuing | -$54.50M |
| Comprehensive Income/Loss | -$323.71M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$74.00K |
| Comprehensive Income/Loss Attributable To Parent | -$323.64M |
| Other Comprehensive Income/Loss | $27.76M |